Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | SCN8A | Q9UQD0 | 8/20 | 0.34 |
| ▸ | SCN1A | P35498 | 7/20 | 0.34 |
| ▸ | SCN5A | Q14524 | 7/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | SCN1B | Q07699 | 2/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.32 |
| ▸ | CYP2J2 | P51589 | 3/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | KIT | P10721 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.32 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27247607 | 0.98 | KDM4C (0.37) | KDM4CMAPK1SCN8ASCN1ASCN5A | |
| SCHEMBL30946182 | 0.98 | KDM4C (0.37) | KDM4CMAPK1SCN8ASCN1ASCN5A | |
| SCHEMBL27247315 | 0.85 | EPHX2 (0.35) | MAPK1GRIN2BGRM5EPHX2CYP2C9 | |
| SCHEMBL30946079 | 0.85 | EPHX2 (0.35) | MAPK1GRIN2BGRM5EPHX2CYP2C9 | |
| SCHEMBL27247504 | 0.85 | KDM4C (0.41) | KDM4CMAPK1SCN8ASCN1ASCN5A | |
| SCHEMBL30946204 | 0.85 | KDM4C (0.41) | KDM4CMAPK1SCN8ASCN1ASCN5A | |
| SCHEMBL27247117 | 0.85 | GRM5 (0.37) | MAPK1GRIN2BGRM5EPHX2CYP2C9 | |
| SCHEMBL30946117 | 0.85 | GRM5 (0.37) | MAPK1GRIN2BGRM5EPHX2CYP2C9 | |
| SCHEMBL30946216 | 0.84 | EPHX2 (0.35) | MAPK1GRIN2BGRM5EPHX2CYP2C9 | |
| SCHEMBL30920146 | 0.83 | GRM5 (0.37) | MAPK1SCN8ASCN1ASCN5AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240199546-A1 | INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF | HERCULES CAPITAL, INC., AS AGENT | 2024-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199546-A1 | INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF | SLC6A19, SLC2A9, SLC6A3 | KDM4C 3802/4885MAPK1 3172/4885SCN8A 593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.